Gastric pH Regulation in Healthy Volunteers
Conditions
Keywords
Proton pump inhibitor (PPI), DLBS2411, gastric pH
Brief summary
This is a 3-arm, double-blind, randomized, controlled, parallel and dose ranging clinical study for 3 days of therapy to investigate the effect of DLBS2411 in gastric pH regulation as well as its safety in healthy volunteers. DLBS2411 has similar mechanism of action with proton-pump inhibitors (PPIs). However, it is hypothetically more potential than PPIs in suppressing gastric acid as our previous preclinical studies with DLBS2411 have proven its effects not only on the activity of H+/K+ ATPase, the enzyme that regulates proton pump in stomach, but also on its gene expression. It is hypothesized that DLBS2411 may benefit on gastric pH regulation in healthy volunteers.
Detailed description
There will be 3 groups of treatment; each group will consist of 18 subjects with the treatment regimens : * Treatment I : 1 caplet of DLBS2411 250 mg and 1 placebo caplet of DLBS2411, once daily * Treatment II : 2 caplets of DLBS2411 250 mg, once daily * Treatment III : 2 placebo caplets of DLBS2411, once daily Clinical examination to evaluate the investigational drug's efficacy will be performed by a 24-hour-gastric pH monitoring after the first dose of study drug administration. Besides, the pH of the gastric fluid will also be measured at the end of study (Day 3 of treatment). Safety examination will be performed at baseline and at end of study. The occurrence of adverse event will be observed during the study. All subjects will be under direct supervision of a medical doctor during the study period.
Interventions
DRUGDLBS2411
1 caplet of DLBS2411 @250 mg and 1 placebo caplet, once daily
DRUGPlacebo DLBS2411
2 placebo caplets of DLBS2411, once daily
Sponsors
Dexa Medica Group
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Male subjects with age of 18-45 years * Healthy as confirmed by vital signs, clinical and laboratory assessments (normal blood pressure, normal plasma glucose level, normal values of all hematological parameters, adequate liver and renal function) * BMI 18-25 kg/m2 * Able to take oral medication
Exclusion criteria
* Gastric pH ≥ 4 at screening * Currently being an active smoker and suffering from chronic alcoholism * History of or currently peptic ulcer * Having clinical diagnosis of Zollinger Ellison syndrome * Taking any H2RAs, PPIs, antacids, or gastric mucosal protectors within 2 weeks prior to screening * Taking any other medicines, supplements, or herbals within 3 days prior to screening * History of gastro-intestinal disturbances necessitating long-term treatment with any acid suppressing medication, antacids, or gastric mucosal protectors * The presence of any chronic diseases * Currently being afflicted by serious infection(s) * Participation in any other clinical studies within 30 days prior to screening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of time over 24 hours during which gastric pH is > 4 | 24 hours | Percentage of time over 24 hours during which gastric pH is \> 4 after a single dose of study medication |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 24-hour median gastric pH | 24 hours | 24-hour median gastric pH after the initial dose of study medication |
| Gastric pH at the end of study | 3 days | Gastric pH after a repeated (3-day) dosing of study medication |
| Change of ECG description from baseline | baseline and 3 days after treatment initiation | ECG will be evaluated at baseline (Day 1st)and at end of study (Day 3rd) |
| Routine haematology | Baseline and 3 days after treatment initiation | Routine haematology (hemoglobin level, hematocrit, erythrocyte count, leucocyte count, differentiation of WBC and platelet count) will be evaluated at baseline and at end of study (Day 3rd) |
| The onset of action | 24 hours | The onset of action, which is defined as time taken to achieve gastric pH of \> 4 after the initial dose of study medication |
| Renal function | Baseline and 3 days after treatment initiation | Renal function (serum creatinine level) will be evaluated at baseline and at end of study (Day 3rd) |
| Urinalysis parameters | Baseline and 3 days after treatment initiation | Urinalysis parameters (urine color, pH, presence of glucose, protein, sediments, epithelial cells, erythrocyte, leucocyte, and others) will be evaluated at baseline and at end of study (Day 3rd) |
| Adverse events | 3 days or until all adverse events have been recovered or stabilized (which ever comes first) | Type and number of adverse events as well as number of subjects experiencing the events will be observed and evaluated during study period (3 days of treatment)and until the end of study or all adverse events have been recovered or stabilized (which ever comes first). |
| Liver function | baseline and 3 days after treatment initiation | Liver function (ALT, AST, γ-GT, and total bilirubin levels) will be evaluated at baseline and at end of study (Day 3rd) |
Countries
Indonesia
Outcome results
None listed